FDA reviews Merck & Co's Keytruda in new 'tumour agnostic' u...

Merck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use in all cancer patients whose tumours have a certain genetic biomarker.

Cancer Research UK cuts research funding as COVID-19 hits in...

Cancer Research UK has cut funding to its research activities, as the charity faces a cut to its income by up to a quarter in the next financial year because of the impact of the coronaviru

New combination trial firms up Venclexta’s prospects in AML

Merck, Pfizer’s Bavencio flunks head and neck cancer trial

AZ's cediranib falls short again in ovarian cancer combinati...

AstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it did not improve survival compared with chemotherapy in advanced ovarian cancer, in

Staying on the cutting edge of oncology advances

Rapidly-changing treatment landscapes in diseases like lung cancer pose challenges for medical education providers, who need to be more adaptable than ever.